Publishing Strategy10 min read•Updated Mar 16, 2026

Clinical Cancer Research Submission Process

Clinical Cancer Research's submission process, first-decision timing, and the editorial checks that matter before peer review begins.

By Associate Professor, Clinical Medicine & Public Health•March 16, 2026

Associate Professor, Clinical Medicine & Public Health

Author context

Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.

Readiness scan

Before you submit to Clinical Cancer Research, pressure-test the manuscript.

Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.

Run Free Readiness ScanAnthropic Privacy Partner. Zero-retention manuscript processing.Open Clinical Cancer Research Guide

Stage	What to check
1. Scope	Manuscript preparation
2. Package	Submission via AACR system
3. Cover letter	Editorial assessment
4. Final check	Peer review

Quick answer: how to submit to Clinical Cancer Research

Clinical Cancer Research uses ScholarOne, but the difficult part is not clicking through the system. The difficult part is submitting a file that clearly behaves like a translational oncology paper rather than a basic cancer paper with clinical language added late.

If the manuscript already links mechanism, validation, and patient consequence cleanly, the portal itself is manageable: choose the right article type, upload a disciplined package, make the translational logic explicit in the cover letter, and check that all reporting elements are complete. If the translational consequence is still mostly aspirational, the paper will look weak before reviewers even start.

That is why this page works best as a process and screening guide together. If you are still deciding whether the journal is realistic, start with the Clinical Cancer Research journal profile first. If the fit is real, use this page to make the submission cleaner and faster.

Before you open the submission portal

Before you touch ScholarOne, make sure the package already answers the questions an editor will ask in the first read.

Item	What to confirm before submission	Why it matters
Translational case	The manuscript shows a credible mechanism-to-clinic connection	This journal rejects papers that are still mostly basic biology
Article type	The file matches the right manuscript category	Misclassified submissions slow the editorial path
Figures	The clinical or translational consequence is visible in the first key figures	Editors should not have to dig for the patient-facing point
Human/clinical reporting	Registration, ethics, cohort definitions, and endpoint logic are complete	Missing reporting elements raise trust questions immediately
Cover letter	The letter states why the paper belongs in Clinical Cancer Research rather than a basic journal	Generic letters waste the strongest part of the editorial pitch
Supporting files	Supplemental data support the claim instead of rescuing it	If critical validation lives only in supplements, the file feels weaker

Also check whether the paper is really ready for a translational audience. A manuscript can be good science and still not be ready for this journal. If the patient consequence is mostly interpretive, the portal step is not the problem. The package itself is.

Step-by-step submission flow

1. Choose the article type honestly

Do not begin by asking what category gives the paper the best chance. Begin by asking what kind of paper this actually is. If it is a full translational story with meaningful validation and oncology consequence, submit it as a full research article. If it is narrower, more focused, or more preliminary, forcing it into the biggest category will not help.

2. Build a manuscript file that makes the translational logic easy to follow

Clinical Cancer Research editors often make an early judgment on whether the manuscript belongs in their lane. The file should make the sequence obvious:

the oncology problem
the mechanistic or biomarker logic
the validation layer
the patient-facing consequence

If that chain is hard to see, the paper is more likely to be treated as a basic cancer manuscript that should live elsewhere.

3. Upload the core files cleanly

ScholarOne is not where you want to discover that your figures, cover letter, or disclosure details are still in flux. Keep the manuscript, figures, tables, and supplements clearly separated and named. Make sure the version uploaded is the version the authors have actually approved.

4. Use the cover letter to frame the journal fit

The cover letter should not retell the manuscript. It should tell the editor why this paper belongs in a translational oncology journal and why the patient consequence is supported by the data already in the file. If you need a better letter structure, the cover letter guide is a better starting point than a generic template.

5. Review metadata carefully

Clinical studies and translational oncology papers often carry more administrative detail than authors expect. Trial registration, ethics, conflict disclosures, funding, and contributor information should match the manuscript exactly. Metadata inconsistencies slow files and make the submission look less controlled.

6. Expect an editorial screen before the serious review work starts

The earliest decision point is usually whether the manuscript already feels clinically meaningful enough for this journal. That means the first page, first figures, and cover letter do a disproportionate amount of work.

Common mistakes and avoidable delays

These are the mistakes that create the most avoidable trouble:

The manuscript is still mostly basic cancer biology. Translational wording alone will not carry it.
The patient consequence is speculative. If the practical implication appears only in the discussion, editors notice.
Validation is too thin for the ambition of the claim. Biomarker or response claims without enough clinical support create instant skepticism.
The figures are mechanistically rich but clinically under-explained. Reviewers can miss the translational case if the file does not stage it clearly.
The cover letter is generic. For this journal, the fit argument matters.
Administrative details are inconsistent. Trial numbers, ethics statements, author affiliations, and disclosures have to align.
The paper tries to sound bigger than the evidence. This journal rewards disciplined translational writing, not inflated clinical language.

If you are unsure whether the fit is solid enough, compare this process page with the Clinical Cancer Research journal profile before you submit.

What editors and reviewers will notice first

The first editorial question is usually not whether the biology is interesting. It is whether the manuscript already justifies a translational oncology audience.

Is the oncology consequence visible early?

Editors notice quickly whether the manuscript explains what changes for patients, treatment selection, biomarker interpretation, or resistance logic. If that consequence is buried, the file feels less ready.

Does the validation package support the claim?

Clinical Cancer Research readers are sensitive to overreach. If the conclusion is big, the validation has to be proportionate. Thin cohorts, fragile translational links, or narrow systems weaken the process before reviewers even debate novelty.

Does the writing feel disciplined?

A strong submission feels controlled. It does not oversell. It does not hide weak points in the supplement. It does not use vague translational language as a substitute for evidence.

Can the first page survive scrutiny?

Before you submit, ask:

Can an editor identify the patient-facing consequence from the abstract and title?
Is the translational bridge visible in the first figures?
Does the cover letter explain why the paper belongs here rather than in a basic or organ-specific alternative?
Would the main claim still feel credible after you remove the most optimistic language?

If the answers are strong, the portal is only the last step. If the answers are weak, the manuscript is not ready for this journal yet.

One last translational screen before upload

Before the corresponding author presses submit, test the paper against the hardest question in this journal family: if the word translational disappeared from the title and cover letter, would the data still force a clinician-facing interpretation?

That question often exposes the last weak point. If the answer depends on future cohorts, future validation, or future therapeutic work, the paper is probably still early. If the answer is already visible in the current figures and tables, the submission is behaving more like a true Clinical Cancer Research package.

One practical way to run that check is to review the package in this order:

title and abstract
first two figures
cover letter
discussion opening

If those four pieces all point to the same patient-facing conclusion, the file is usually much stronger. If they point in different directions, fix the package before upload and before asking the journal to interpret the story for you.

Another simple check is to ask whether an oncology editor could explain the patient consequence in one sentence after reading only the abstract and first figure legend. If not, the submission package is still asking the journal to do too much interpretive work on your behalf before review even starts.